| 2019-SINT-68535 | |
| Researchers at Purdue University have developed novel antimicrobial agents to solve the continued problem of drug-resistant bacterial strains; approximately 20,000 people die in the US every year from drug-resistant infections. These antimicrobial agents potently inhibit bacterial growth in several species, including drug-resistant strains, at concentrations as low as 0.0675 micrograms per milliliter. This family of compounds contains both bactericidal and bacteriostatic agents. Advantages: -Inhibits drug resistant bacteria strains -Kills bacteria at low concentration Potential Applications: -Antimicrobial Agent Related Publication: Potent trifluoromethoxy, trifluoromethylsulfonyl, trifluoromethylthio and pentafluorosulfanyl containing (1,3,4-oxadiazol-2-yl)benzamides against drug-resistant Gram-positive bacteria RSC Med. Chem., 2020,11, 102-110 DOI: 10.1039/C9MD00391F |
|
|
|
|
Apr 24, 2020
PCT-Patent
WO
(None)
(None)
Apr 26, 2019
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |